Role of metformin for weight management in patients without type 2 diabetes

Annals of Pharmacotherapy

Volumn 42, Issue 6, 2008, Pages 817-826

  Desilets, Alicia R ^a   Dhakal Karki, Sushmita ^b   Dunican, Kaelen C ^b  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Metabolic syndrome; Metformin; Obesity

Indexed keywords

FLUOXETINE; METFORMIN; MEVINOLIN; PLACEBO; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

BLOOD PRESSURE; CLINICAL TRIAL; DATA EXTRACTION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; METABOLIC SYNDROME X; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; WAIST CIRCUMFERENCE; WEIGHT CONTROL; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANTI-OBESITY AGENTS; BODY WEIGHT; CLINICAL TRIALS AS TOPIC; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; OBESITY; OVERWEIGHT; RESEARCH DESIGN; WEIGHT LOSS;

EID: 44649106470     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K656     Document Type: Review

References (57)

1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-55.
2. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA 2002;288:1728-32.
3. Ogden CL, Carroll MD, Flegal KM. Epidemiologic trends in overweight and obesity. Endocrinol Metab Clin North Am 2003;32:741-60, vii.
4. National Institutes of Health; National Heart, Lung and Blood Institute; North American Association for the Study of Obesity. The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. NIH Publication 00-4084, October 2000. www.nhlbi.nih.gov/guidelines/obesity/ prctgd_c.pdf (accessed 2007 Nov 28).
5. Centers for Disease Control and Prevention. About BMI for children and teens. www.cdc.gov/nccdphp/dnpa/bmi/childrens_BMI/about_childrens_BMI.htm (accessed 2007 Nov 28).
6. United States Department of Health and Human Services. Overweight and obesity: health consequences. www.surgeongeneral.gov/topics/obesity/ calltoaction/fact_consequences.htm (accessed 2007 Nov 28).
7. Giles TD, Sander GE. Pathophysiologic, diagnostic, and therapeutic aspects of the metabolic syndrome. J Clin Hypertens 2005;7:669-78.
8. Lau DC, Yan H, Dhillon B. Metabolic syndrome: a marker of patients at high cardiovascular risk. Can J Cardiol 2006;22(suppl B):85B-90B.
9. Bianchi C, Penno G, Romero F, Del Prato S, Miccoli R. Treating the metabolic syndrome. Exp Rev Cardiovasc Ther 2007;5:491-506.
10. Williamson DF, Serdula MK, Anda RF, Levy A, Byers T. Weight loss attempts in adults: goals, duration, and rate of weight loss. Am J Public Health 1992;82:1251-7.
11. Miller WC, Koceja DM, Hamilton EJ. A meta-analysis of the past 25 years of weight loss research using diet, exercise or diet plus exercise intervention. Int J Obes Relat Metab Disord 1997;21:941-7.
12. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005;142:532-46.
13. FDA CDER Division of Metabolic and Endocrine Drug Products (HFD-510). Clinical review for NDA 20-766/S018. www.fda.gov/cder/foi/esum/2003/20766 se5-018_orlistat_BPCA_CLINICAL_ltr.pdf (accessed 2007 Nov 28).
14. Willms B, Ruge D. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabetic Med 1999;16:755-61.
15. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487-93.
16. Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 2007;13:444-50.
17. Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007;29:139-53.
18. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8:436-47.
19. Ratner RE, Maggs D, Nielsen LL, et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006;8:419-28.
20. Nichols GA, Gomez-Caminero A. Weight changes following the initiation of new anti-hyperglycaemic therapies. Diabetes Obes Metab 2007;9:96-102.
21. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK prospective diabetes study (UKPDS) group. Lancet 1998;352:854-65.
22. Tankova T. Current indications for metformin therapy. Rom J Intern Med 2003;41:215-25.
23. United Kingdom prospective diabetes study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom prospective diabetes study group. Ann Intern Med 1998;128:165-75.
24. Glueck CJ, Fontaine RN, Wang P, et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 2001;50:856-61.
25. Charles MA, Eschwege E, Grandmottet P, et al. Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. Diabetes Metab Res Rev 2000;16:2-7.
26. Lord J, Wilkin T. Metformin in polycystic ovary syndrome. Curr Opin Obstet Gynecol 2004;16:481-6.
27. Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001;24:489-94.
28. Srinivasan S, Ambler GR, Baur LA, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006;91:2074-80.
29. Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:2767-74.
30. Munro JF, MacCuish AC, Marshall A, Wilson EM, Duncan LJ. Weight-reducing effect of diguanides in obese non-diabetic women. Br Med J 1969;2:13-5.
31. Lawson AA, Strong JA, Peattie P, Roscoe P, Gibson A. Comparison of fenfluramine and metformin in treatment of obesity. Lancet 1970;2:437-41.
32. Tankova T, Dakovska L, Kirilov G, Koev D. Metformin in the treatment of obesity in subjects with normal glucose tolerance. Rom J Intern Med 2003;41:269-75.
33. Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002;4:49-55.
34. Sari R, Balci MK, Coban E, Yazicioglu G. Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women. Int J Obes Relat Metab Disord 2004;28:1059-63.
35. Dastjerdi MS, Kazemi F, Najafian A, Mohammady M, Aminorroaya A, Amini M. An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction. Int J Obes 2007;31:713-7.
36. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
37. Fujimoto WY, Jablonski KA, Bray GA, et al. Body size and shape changes and the risk of diabetes in the diabetes prevention program. Diabetes 2007;56:1680-5.
38. Fontbonne A, Charles MA, Juhan-Vague I, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO study group. Diabetes Care 1996;19:920-6.
39. Charles MA, Morange P, Eschwege E, Andre P, Vague P, Juhan-Vague I. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 study. Biguanides and the prevention of the risk of obesity. Diabetes Care 1998;21:1967-72.
40. Carlsen SM, Grill V, Folling I. Evidence for dissociation of insulin- and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease. Diabetes Res Clin Prac 1998;39:47-54.
41. Lehtovirta M, Forsen B, Gullstrom M, et al. Metabolic effects of metformin in patients with impaired glucose tolerance. Diabetic Med 2001;18:578-83.
42. Morel Y, Golay A, Perneger T, et al. Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance. Diabetic Med 1999;16:650-5.
43. Mogul HR, Peterson SJ, Weinstein BI, Li J, Southren AL. Long-term (2-4 year) weight reduction with metformin plus carbohydrate-modified diet in euglycemic, hyperinsulinemic, midlife women (syndrome W). Heart Dis 2003;5:384-92.
44. Schuster D, Gaillard T, Rhinesmith S, Habash D, Osei K. Impact of metformin on glucose metabolism in nondiabetic, obese African Americans: a placebo-controlled, 24-month randomized study. Diabetes Care 2004;27:2768-9.
45. Rodriguez Y, Giri M, Feyen E, Christophe AB. Effect of metformin vs placebo treatment on serum fatty acids in non-diabetic obese insulin resistant individuals. Prostaglandins Leukot Essent Fatty Acids 2004;71:391-7.
46. Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the diabetes prevention program randomized trial. Ann Intern Med 2005;142:611-9.
47. Hoffmann IS, Alfieri AB, Cubeddu LX. Effects of lifestyle changes and metformin on salt sensitivity and nitric oxide metabolism in obese salt-sensitive Hispanics. J Hum Hypertens 2007;21:571-8.
48. Giugliano D, De Rosa N, Di Maro G, et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 1993;16:1387-90.
49. Lutjens A, Smit JL. Effect of biguanide treatment in obese children. Helv Paediatr Acta 1977;31:473-80.
50. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001;50:1457-61.
51. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001;107:E55[1-7].
52. Lustig RH, Mietus-Snyder ML, Bacchetti P, Lazar AA, Velasquez-Mieyer PA, Christensen ML. Insulin dynamics predict body mass index and z-score response to insulin suppression or sensitization pharmacotherapy in obese children. J Pediatr 2006;148:23-9.
53. Fu JF, Liang L, Zou CC, et al. Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention. Int J Obes (Lond) 2007;31:15-22.
54. Harden KA, Cowan PA, Velasquez-Mieyer P, Patton SB. Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents. J Am Acad Nurse Pract 2007;19:368-77.
55. Rodriguez G, Moreno LA, Blay MG, et al. Body composition in adolescents: measurements and metabolic aspects. Int J Obes Relat Metabol Disord 2004;28(suppl 3):S54-8.
56. Weiss R, Taksali SE, Dufour S, et al. The "obese insulin-sensitive" adolescent: importance of adiponectin and lipid partitioning. J Clin Endocrinol Metab 2005;90:3731-7.
57. Levri KM, Slaymaker E, Last A, et al. Metformin as treatment for overweight and obese adults: a systematic review. Ann Fam Med 2005;3:457-61.